Pfizer, Inc. (PFE) Shares Sold by Adirondack Trust Co.

Adirondack Trust Co. decreased its stake in Pfizer, Inc. (NYSE:PFE) by 5.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,426 shares of the biopharmaceutical company’s stock after selling 1,178 shares during the period. Adirondack Trust Co.’s holdings in Pfizer were worth $719,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Canada Pension Plan Investment Board raised its position in Pfizer by 249.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock valued at $359,871,000 after purchasing an additional 7,649,416 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in Pfizer by 6.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 33,274,658 shares of the biopharmaceutical company’s stock valued at $1,117,696,000 after purchasing an additional 2,013,835 shares during the last quarter. Boston Partners raised its position in Pfizer by 7.3% in the 1st quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock valued at $830,071,000 after purchasing an additional 1,649,801 shares during the last quarter. Sanders Capital LLC raised its position in Pfizer by 10.8% in the 2nd quarter. Sanders Capital LLC now owns 16,933,077 shares of the biopharmaceutical company’s stock valued at $626,222,000 after purchasing an additional 1,644,036 shares during the last quarter. Finally, Bank of Nova Scotia raised its position in Pfizer by 325.9% in the 1st quarter. Bank of Nova Scotia now owns 1,934,514 shares of the biopharmaceutical company’s stock valued at $66,180,000 after purchasing an additional 1,480,258 shares during the last quarter. Institutional investors and hedge funds own 69.10% of the company’s stock.

Several research firms recently commented on PFE. BMO Capital Markets reiterated a “buy” rating and issued a $39.00 price target on shares of Pfizer in a research report on Friday. J P Morgan Chase & Co set a $39.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, November 1st. Jefferies Group LLC set a $39.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research report on Wednesday, November 1st. Goldman Sachs Group, Inc. (The) set a $36.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research report on Wednesday, November 1st. Finally, UBS AG set a $38.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $38.48.

ILLEGAL ACTIVITY NOTICE: This report was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/11/12/pfizer-inc-pfe-shares-sold-by-adirondack-trust-co.html.

Shares of Pfizer, Inc. (NYSE:PFE) opened at $35.18 on Friday. The company has a market cap of $209,816.89, a PE ratio of 14.08, a P/E/G ratio of 2.49 and a beta of 1.01. Pfizer, Inc. has a 12 month low of $30.51 and a 12 month high of $36.78. The company has a quick ratio of 1.06, a current ratio of 1.34 and a debt-to-equity ratio of 0.58.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.67%. The firm’s revenue was up .9% on a year-over-year basis. During the same period in the prior year, the company earned $0.61 EPS. equities analysts anticipate that Pfizer, Inc. will post 2.59 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be paid a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.64%. Pfizer’s payout ratio is 79.01%.

In related news, insider Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $249,900.00. Following the sale, the insider now directly owns 132,124 shares of the company’s stock, valued at approximately $4,492,216. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the sale, the insider now directly owns 117,432 shares in the company, valued at $4,145,349.60. The disclosure for this sale can be found here. Over the last three months, insiders sold 374,621 shares of company stock worth $12,796,098. 0.06% of the stock is owned by corporate insiders.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply